Company: IMCR
Filing Date: 2025-05-07
Form Type: 10-Q
Source: 0001671927-25-000009
Chunk: 16

Company: Immunocore Holdings plc
Filing Date: 2025-05-07
Form: 10-Q
Item: Part I, Item 1
Chunk 16
---
Item 1.    Financial Statements

Immunocore Holdings plc

Condensed Consolidated Balance Sheets

(Unaudited) (In thousands, except share and per share data)

March 31,2025December 31,2024AssetsCurrent assetsCash and cash equivalents$476,845 $455,731 Marketable securities360,185 364,645 Accounts receivable, net63,094 63,009 Prepaid expenses and other current assets41,697 41,033 Inventory, net6,804 5,446 Total current assets948,625 929,864 Property and equipment, net9,770 10,092 Operating lease right of use assets, net38,126 37,643 Deferred tax assets, net14,355 14,790 Other non-current assets17,132 17,117 Total assets$1,028,008 $1,009,506 Liabilities and shareholders’ equityCurrent liabilitiesAccounts payable$29,105 $25,100 Accrued expenses and other current liabilities118,341 185,534 Operating lease liabilities, current1,717 1,547 Total current liabilities149,163 212,181 Accrued expenses, non-current62,476 — Deferred revenue, non-current 5,612 5,434 Operating lease liabilities, non-current40,748 40,162 Interest-bearing loans and borrowings391,530 391,013 Total liabilities649,529 648,790 Commitments and contingencies (Note 10)Shareholders’ equityOrdinary shares (voting and non-voting), £0.002 par value, most recent authority to allot up to a maximum nominal value of £97,234 and £97,454 shares as of March 31, 2025 and December 31, 2024, respectively, and 50,184,609 and 50,064,860 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively. 135 135 Deferred shares, £0.0001 par value, 5,793,501 shares authorized, issued and outstanding as of March 31, 2025 and December 31, 2024.1 1 Additional paid-in capital1,202,171 1,190,104 Accumulated deficit(790,738)(795,